ArticleJournal of pharmaceutical sciences2026
Stabilization of spray-dried monoclonal antibody formulations with polymeric excipients.
Article in Journal of pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Spray drying is an emerging continuous manufacturing approach with significant potential for producing stable solid formulations of biologic drug products such as peptides, proteins and oligonucleotides. However, these sensitive molecules on exposure to thermal, shear, and interfacial stresses during spray drying may experience structural perturbations that compromise long-term stability. This study evaluated several polymeric excipients as stabilizers in spray-dried monoclonal antibody formulations and compared their performance with conventional sugar excipients, trehalose and mannitol. Formulations were prepared at a 1:1 (w/w) protein-to-excipient ratio and spray dried, and the resulting powders were subjected to accelerated storage at 40 °C. Particle size distribution, morphology, and residual moisture content were characterized. Protein physical stability and secondary structure were evaluated using size exclusion chromatography and solid-state Fourier transform infrared spectroscopy, respectively. Solid-state nuclear magnetic resonance spectroscopy and X-ray photoelectron spectroscopy were used to study protein-excipient phase miscibility and particle surface composition, respectively, in the spray-dried solids. Hydrolyzed gelatin provided the most robust stabilization of the mAb, resulting in a fivefold reduction in monomer loss compared to trehalose after 90 days storage at 40 °C. (2-Hydroxypropyl)-β-cyclodextrin showed stabilization comparable to trehalose while reducing the mAb surface exposure. High molecular weight polyvinylpyrrolidone (PVP K90) showed better mAb stabilization compared to its low molecular weight grade (PVP K30). Whereas dextran, sodium carboxymethyl cellulose, and hydroxypropyl methylcellulose were less effective in their ability to stabilize the mAb. These findings highlight the critical role of excipient selection in improving the stability of spray-dried monoclonal antibody formulations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.